Updated

Analysts say Vertex Pharmaceuticals' acquisition of Crinetics creates a new growth engine for the company beyond its traditional cystic fibrosis franchise. The deal is viewed as diversifying Vertex's pipeline and revenue base. The transaction reflects broader consolidation activity in the biotech sector as large-cap pharma companies seek new growth avenues outside legacy therapeutic areas.